Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ~ modulates | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| PF-04236921 | ↓ inhibits | Mechanistic | DGIdb | |
| MRA 003 US | ↓ inhibits | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| SILTUXIMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MEDI-5117 | ↓ inhibits | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| BIAFINE CREAM | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ? unclear | Mechanistic | DGIdb | |
| ELSILIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA PREPARATION | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FENOFIBRATE MICRONIZED | ? unclear | Mechanistic | DGIdb | |
| VITAMIN K | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| ARSENIC TRIOXIDE | ? unclear | Mechanistic | DGIdb | |
| DIHYDROSPHINGOSINE | ? unclear | Mechanistic | DGIdb | |
| LEVOFLOXACIN ANHYDROUS | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 173 agents ranked by evidence tier.
PTGS2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CARPROFEN | ↓ inhibits | Mechanistic | 102.0 nM (IC50) | DGIdb |
| INDOMETHACIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| DARBUFELONE | ? unclear | Mechanistic | DGIdb | |
| MEFENAMIC ACID | ↓ inhibits | Mechanistic | DGIdb | |
| MECLOFENAMATE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| CAPECITABINE | ? unclear | Mechanistic | DGIdb | |
| PIRPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| ESFLURBIPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| SULFASALAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| BROMFENAC | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN, SODIUM SALT | ↓ inhibits | Mechanistic | DGIdb | |
| ALOXIPRIN | ↓ inhibits | Mechanistic | DGIdb | |
| TENOXICAM | ? unclear | Mechanistic | DGIdb | |
| FLURBIPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| SALICYLIC ACID | ? unclear | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| DEXKETOPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| ETORICOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| LUMIRACOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| SUPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| NS-398 | ? unclear | Mechanistic | DGIdb | |
| NABUMETONE | ↓ inhibits | Mechanistic | DGIdb | |
| URSOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| IBUPROFEN LYSINE | ↓ inhibits | Mechanistic | DGIdb | |
| ACECLOFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| IBUFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| BALSALAZIDE | ? unclear | Mechanistic | DGIdb | |
| DIFLUNISAL | ↓ inhibits | Mechanistic | DGIdb | |
| BALSALAZIDE DISODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| VACCINE | ? unclear | Mechanistic | DGIdb | |
| KETOROLAC TROMETHAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| BENZYDAMINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TIAPROFENIC ACID | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| NAPROXCINOD | ↓ inhibits | Mechanistic | DGIdb | |
| IGURATIMOD | ↓ inhibits | Mechanistic | DGIdb | |
| ETODOLAC | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC ETALHYALURONATE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ROFECOXIB | ↓ inhibits | Mechanistic | 530.0 nM (IC50) | DGIdb |
Showing top 40 of 299 agents ranked by evidence tier.
SCN9A
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| MERETHOXYLLINE PROCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| ETIDOCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| FOSPHENYTOIN | ↓ inhibits | Mechanistic | DGIdb | |
| VERATRIDINE | ↑ activates | Mechanistic | DGIdb | |
| ORPHENADRINE CITRATE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENACEMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| LACOSAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| VIXOTRIGINE | ↓ inhibits | Mechanistic | DGIdb | |
| DSP-2230 | ↓ inhibits | Mechanistic | DGIdb | |
| SAXITOXIN | ↓ inhibits | Mechanistic | DGIdb | |
| ESLICARBAZEPINE ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| SAFINAMIDE | ? unclear | Mechanistic | DGIdb | |
| LIDOCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| RILUZOLE | ↓ inhibits | Mechanistic | DGIdb | |
| ROPIVACAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| FUNAPIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DYCLONINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| EVENAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PROPOFOL | ? unclear | Mechanistic | DGIdb | |
| AM-6120 | ↓ inhibits | Mechanistic | DGIdb | |
| RG7893 | ↓ inhibits | Mechanistic | DGIdb | |
| RG6029 | ↓ inhibits | Mechanistic | DGIdb | |
| QUINIDINE SULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| ZONISAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| NERISPIRDINE | ↓ inhibits | Mechanistic | DGIdb | |
| RALFINAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DS-1971A | ↓ inhibits | Mechanistic | DGIdb | |
| HEXYLCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| MEPIVACAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PROCAINAMIDE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PROPAFENONE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| LIDOCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| QUINIDINE GLUCONATE | ↓ inhibits | Mechanistic | DGIdb | |
| PRILOCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| ETHOTOIN | ↓ inhibits | Mechanistic | DGIdb | |
| PF-05089771 | ↓ inhibits | Mechanistic | DGIdb | |
| DICHLOROBENZYL ALCOHOL | ↓ inhibits | Mechanistic | DGIdb | |
| RANOLAZINE | ? unclear | Mechanistic | DGIdb | |
| PRILOCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ORPHENADRINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 271 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NERELIMOMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CROMOLYN SODIUM | ? unclear | Mechanistic | DGIdb | |
| PLACULUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ALTEPLASE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| GENTAMICIN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| BUPIVACAINE | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | 85000.0 nM (IC50) | DGIdb |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| PYRAZINAMIDE | ? unclear | Mechanistic | DGIdb | |
| GLIMEPIRIDE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| LENERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ADALIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ? unclear | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| LENABASUM | ? unclear | Mechanistic | DGIdb | |
| MAGNESIUM SULFATE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| PICIBANIL | ? unclear | Mechanistic | DGIdb | |
| FLUOCINOLONE ACETONIDE | ? unclear | Mechanistic | DGIdb | |
| MILTEFOSINE | ? unclear | Mechanistic | DGIdb | |
| HOMIDIUM BROMIDE | ? unclear | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| PEGSUNERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC HORMONE | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| ABBV-257 | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| COVA322 | ? unclear | Mechanistic | DGIdb | |
| HYDROXYCHLOROQUINE | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB | ? unclear | Mechanistic | DGIdb | |
| AN0128 | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SORAFENIB | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 277 agents ranked by evidence tier.
TRPV1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| BENZYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| ACETAMINOPHEN | ↑ activates | Mechanistic | DGIdb | |
| POLYGODIAL | ? unclear | Mechanistic | DGIdb | |
| PROPOFOL | ? unclear | Mechanistic | DGIdb | |
| SAF312 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-15300 | ? unclear | Mechanistic | DGIdb | |
| AZD1386 | ↓ inhibits | Mechanistic | DGIdb | |
| TIVANISIRAN | ↓ inhibits | Mechanistic | DGIdb | |
| MAVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| MR-1817 | ↓ inhibits | Mechanistic | DGIdb | |
| FERRUGINENE B | ? unclear | Mechanistic | DGIdb | |
| CAPSAICIN | ↑ activates | Mechanistic | 19.95 nM (EC50) | DGIdb |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| PHENETHYLISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| VOACANGINE | ? unclear | Mechanistic | DGIdb | |
| RESINIFERATOXIN | ↑ activates | Mechanistic | 23.1 nM (Ki) | DGIdb |
| DWP05195 | ↓ inhibits | Mechanistic | DGIdb | |
| XEN-D0501 | ↓ inhibits | Mechanistic | DGIdb | |
| PAC-14028 | ↓ inhibits | Mechanistic | DGIdb | |
| SB-705498 | ↓ inhibits | Mechanistic | DGIdb | |
| MASOPROCOL | ? unclear | Mechanistic | DGIdb | |
| ALLYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| NGD-8243 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-6211 | ↓ inhibits | Mechanistic | DGIdb | |
| RESERPINE | ? unclear | Mechanistic | DGIdb | |
| NABIXIMOLS | ? unclear | Mechanistic | DGIdb | |
| A425619 | ? unclear | Mechanistic | DGIdb | |
| PHE377 | ↓ inhibits | Mechanistic | DGIdb | |
| ANTISENSE OLIGONUCLEOTIDES | ? unclear | Mechanistic | DGIdb | |
| WORTMANNIN | ? unclear | Mechanistic | DGIdb | |
| JTS-653 | ↓ inhibits | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| AMG517 | ↓ inhibits | Mechanistic | DGIdb | |
| CAPSAZEPINE | ? unclear | Mechanistic | 120.0 nM (Ki) | DGIdb |
| ZUCAPSAICIN | ↑ activates | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL191534 | ? unclear | Mechanistic | DGIdb | |
| ABT-102 | ↓ inhibits | Mechanistic | DGIdb | |
| ISOPROPYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 160 agents ranked by evidence tier.
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is l...
Background: \- Orthopedic procedures are common in the United States. These include joint replacement and spine surgeries. Researchers want to study data about these procedures over time. They want to see if treatment has gotten better. They also want to find ways to change the care that people get...
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have sp...
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor o...
Temporomandibular disorders (TMD) encompass a group of conditions involving the masticatory muscles, temporomandibular joint (TMJ), and associated structures. TMD is the most common cause of non-odontogenic orofacial pain and is the second most commonly occurring musculoskeletal condition. Up to 70%...
Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System.
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to tre...
This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory D...
The investigators plan to conduct a randomized controlled trial to evaluate the effectiveness and the cost effectiveness of an on-line eLearning program (entitled Employment and Arthritis: Making it Work) designed to help people with inflammatory arthritis stay employed. The program also includes as...
Chronic inflammatory rheumatic diseases (IRDs), such as rheumatoid arthritis and spondyloarthritis, can cause pain, fatigue, and mobility issues, significantly impacting patients' quality of life. Physical activity is an important part of managing these conditions, as it helps reduce pain, maintain ...
This project will be a multi-center, prospective longitudinal cohort for all patients undergoing primary shoulder instability surgery, excluding isolated SLAP repairs. We will be looking for risk factors for recurrent instability, revision surgery, and poor outcomes. Patients will be asked to comple...
* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ...
The goal of this clinical trial is to learn if a gel containing Piroxicam plus Counterirritant (warming/cooling ingredients) is as effective and safe as two other common anti-inflammatory gels for treating acute muscle, bone, and joint pain in adults aged 18-60. The main questions it aims to answer ...
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other antica...
This study is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up study, which is designed to collect safety and performance data at baseline, surgery, immediate post-op and annually through 10 years post-operation. Data collected from this s...
Searched directly from “Other Musculoskeletal Disorders” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 5-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."